Brief: Transgene Q3 Operating Income Up At 2.3 Million Euros

Transgene SA

07/11/2022 06:53

Nov 7 (Reuters) - Transgene SA  TRNG.PA :
    * REPORTS BUSINESS UPDATE AND Q3 2022 FINANCIAL POSITION
    * POSITIVE RESULT FROM INTERIM ANALYSIS AND REDUCTION OF
SIZE OF
PHASE II TRIAL EVALUATING TG4001 + AVELUMAB VERSUS AVELUMAB IN
HPV-POSITIVE ANOGENITAL CANCERS
    * EUR 36.3 MILLION IN CASH AND CASH EQUIVALENTS AS OF
SEPTEMBER
30, 2022
    * FINANCIAL VISIBILITY UNTIL END OF 2023
    * TRIAL IS NOW EXPECTED TO ENROLL A TOTAL OF 120 PATIENTS
COMPARED
TO INITIAL FORECAST OF 150 PATIENTS
    * Q3 OPERATING INCOME EUR 2.3 MILLION VERSUS EUR 1.8 MILLION
YEAR
AGO

Source text for Eikon:  ID:nBw7RvLKFa 
Further company coverage:  TRNG.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))